

DAFTAR PUSTAKA

- 1 Cassidy JT, Lindsley CB. Juvenile Dermatomyositis. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB (eds). *Textbook of Pediatric Rheumatology*. Elsevier Inc.: Philadelphia, 2005, pp 407–441.
- 2 Mendez EP, Lipton R, Ramsey-goldman R, Roettcher P, Bowyer S, Dyer A *et al*. US Incidence of Juvenile Dermatomyositis , 1995 – 1998 : Results From the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. *Arthritis Rheum* 2003; **49**: 300–305.
- 3 Symmons DPM, Sillst JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nation-wide study. *Br J Rheumatol* 1995; **34**: 732–6.
- 4 Ramona F, Prakoeswa S, Danarti R. Juvenile Dermatomiyoisitis: penegakan diagnosis. *Biomedika* 2014; **6**: 31–37.
- 5 Sanner H. *Outcomes and prognostic factors in Juvenile Dermatomyositis Doctoral thesis by*. 2010.
- 6 Choi YJ, Yoo W. Panniculitis , A Rare Presentation of Onset and Exacerbation of Juvenile Dermatomyositis : A Case Report and Literature Review. *Arch Rheumatol* 2018; **33**: 367–371.
- 7 Ghali FE, Reed AM, Groben PA, Mccauliffe DP, Hill C, Carolina N. Panniculitis in Juvenile Dermatomyositis. *Pediatr Dermatol* 1999; **16**: 270–272.
- 8 Rosa Neto NS, Goldenstein-Schainberg C. Juvenile dermatomyositis: review and update of the pathogenesis and treatment. *Rev Bras Reumatol* 2010; **50**: 299–312.
- 9 Wedderburn LR, Rider LG. Juvenile Dermatomyositis: New Developments in Pathogenesis, Assessment and Treatment. *Best Pract Res Clin Rheumatol* 2014; **71**: 3831–3840.
- 10 Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic infl ammatory myopathies of childhood. *Lancet* 2008; **371**: 2201–12.
- 11 Martin N, Li CK, Wedderburn LR. Juvenile dermatomyositis : new insights

- and new treatment strategies. *Ther Adv Musculoskelet Dis* 2012; **4**: 41–50.
- 12 Polcari IC, Stein SL. Panniculitis in childhood. *Dermatology Ther* 2010; **23**: 356–367.
 - 13 Wu Q, Wedderburn LR, Mccann LJ. Best Practice & Research Clinical Rheumatology Juvenile dermatomyositis : Latest advances. *Best Pract Res Clin Rheumatol* 2017. doi:10.1016/j.berh.2017.12.003.
 - 14 Mccann LJ, Juggins AD, Maillard SM, Wedderburn LR, Davidson JE, Murray KJ *et al.* The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)— clinical characteristics of children recruited within the first 5 yr. *Rheumatology* 2006; **45**: 1255–1260.
 - 15 Neto NSR, Goldenstein-Schainberg C. Juvenile dermatomyositis: Review and update of the pathogenesis and treatment. *Rev Bras Reumatol* 2010; **50**: 305–312.
 - 16 Dalakas MC. Inflammatory Muscle Diseases. *N Engl J Med* 2015; **372**: 1734–47.
 - 17 Chari G, Laude TA. Juvenile Dermatomyositis : A Review. *Int Pediatr* 2000; **15**: 21–25.
 - 18 Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C *et al.* Long-Term Outcome and Prognostic Factors of Juvenile Dermatomyositis : A Multinational , Multicenter Study of 490 Patients. *Arthritis Care Res* 2010; **62**: 63–72.
 - 19 Enders FB, Bader-meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM *et al.* Consensus-based recommendations for the management of juvenile dermatomyositis. *Ann Rheum Dis* 2017; **76**: 329–340.
 - 20 Kim S, El-hallak M, Dedeoglu F, Zurakowski D, Fuhlbrigge RC, Sundel RP. Complete and Sustained Remission of Juvenile Dermatomyositis Resulting From Aggressive Treatment. *Arthritis Rheum* 2009; **60**: 1825–1830.
 - 21 Huber AM, Robinson angela B, Reed AM, Abramson L, Bout-Tabaku S, Carrasco R *et al.* Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. *Arthritis Care Res* 2012; **64**:

546–553.

- 22 Huber AM, Giannini EH, Bowyer SL, Kim S, Lang B, Lindsley CB *et al.* Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a children's arthritis and rheumatology research alliance consensus conference. *Arthritis Care Res* 2010; **62**: 219–225.
- 23 Sun C, Lee J, Yang Y, Yu H, Wang L, Lin Y *et al.* Juvenile Dermatomyositis : A 20-year Retrospective Analysis of Treatment and Clinical Outcomes. *Pediatr Neonatol* 2015; **56**: 31–39.
- 24 Polychronopoulou T. Physiotherapy in Juvenile Dermatomyositis. *J Res Pract Musculoskelet Syst* 2017; **1**: 14–18.
- 25 Huber AM, Lang B, Blanc CMALE, Birdi N, Bolaria RK, Malleson P *et al.* Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. *Arthritis Rheum* 2000; **43**: 541–549.
- 26 Callen JP, Wortmann RL. Dermatomyositis. *Clin Dermatol* 2006; **24**: 363–373.
- 27 Habibi S, Ramanan A V. Juvenile dermatomyositis : A review of clinical features and. *Indian J Rheumatol* 2012; **7**: 80–86.
- 28 Enders FB, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM *et al.* Consensus-based recommendations for the management of juvenile dermatomyositis. *Ann Rheum Dis* 2017; **76**: 329–340.
- 29 Dvergsten JA, Reed AM. Progress and prognosis in juvenile dermatomyositis. *Int J Clin Rheumatol* 2014; **9**: 567–584.
- 30 Mathiesen P, Hegaard H, Herlin T, Zak M, Pedersen FK, Nielsen S. Long-term outcome in patients with juvenile dermatomyositis : a cross-sectional follow-up study. *Scand J Rheumatol* 2012; **41**: 50–58.
- 31 Stringer E, Singh-Grewal D, Feldman BM. Predicting the course of juvenile dermatomyositis significance of early clinical laboratory features. *Arthritis Rheum* 2008; **58**: 3585–3592.
- 32 Lazarevic D, Pistorio A, Palmisani E, Miettunen P, Pilkington C, Wulffraat NM *et al.* The PRINTO criteria for clinically inactive disease in juvenile

- dermatomyositis. *Ann Rheum Dis* 2013; **72**: 686–693.
- 33 Almeida B, Campanilho-marques R, Arnold K, Pilkington CA, Wedderburn LR, Nistala K. Analysis of Published Criteria for Clinically Inactive Disease in a Large Juvenile Dermatomyositis Cohort Shows That Skin Disease Is Underestimated. *Arthritis Rheumatol* 2015; **67**: 2495–2502.
 - 34 Almeida B, Arnold K, Campanilho-marques R, Wedderburn L, Pilkington C. Clinically inactive disease in juvenile dermatomyositis – a proposed revision to the printo criteria. *Pediatr Rheumatol* 2014; **12**: P88.
 - 35 Pistorio A, Ravelli A, Apaz MT, Saad-magalha C, Sato JDEO, Marcantoni MB *et al.* Health-Related Quality of Life of Patients With Juvenile Dermatomyositis : Results From the Paediatric Rheumatology International Trials Organisation Multinational Quality of Life. *Arthritis Rheum* 2009; **61**: 509–517.
 - 36 Kountz-edwards S, Aoki C, Gannon C, Gomez R, Cordova M, Packman W. The family impact of caring for a child with juvenile dermatomyositis. *Chronic Illn* 2017; **0**: 1–13.
 - 37 Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM. Disease activity score for children with juvenile dermatomyositis: Reliability and validity evidence. *Arthritis Rheum* 2003; **49**: 7–15.
 - 38 Sanner H, Kirkhus EVA, Merckoll E, Tollisen A, Røisland M, Lie BA *et al.* Long-Term Muscular Outcome and Predisposing and Prognostic Factors in Juvenile Dermatomyositis : A Case – Control Study. *Arthritis Care Res* 2010; **62**: 1103–1111.
 - 39 Hasija R, Pistorio A, Ravelli A, Demirkaya E, Khubchandani R, Guseinova D *et al.* Therapeutic Approaches in the Treatment of Juvenile Dermatomyositis in Patients With Recent-Onset Disease and in Those Experiencing Disease Flare An International Multicenter PRINTO Study. *Arthritis Rheum* 2011; **63**: 3142–3152.
 - 40 Bowyer SL, Blane CE, Sullivan DB. Childhood dermatomyositis: Factors predicting functional outcome and development of dystrophic calcification. *J Pediatr* 1983; **103**: 882–8.

- 41 Bugni VM, Ozaki LS, Okamoto, Karine YK Barbosa, Cássia M. P. L. Hilário MOE, Len CA, Terreri TM. Factors associated with adherence to treatment in children and adolescents with chronic rheumatic diseases. *J Pediatr (Rio J)* 2012; **88**: 483–8.
- 42 Wagner J, Chaney J, Hommel K, Andrews N, Jarvis J, Wagner J *et al.* Children's Health Care A Cognitive Diathesis-Stress Model of Depressive Symptoms in Children and Adolescents With Juvenile Rheumatic Disease A Cognitive Diathesis-Stress Model of Depressive Symptoms in Children and Adolescents With Juvenile Rheumatic Di. *Child Heal Care* 2007; **36**: 45–62.
- 43 Filocamo G, Consolaro A, Ferrari C, Ravelli A, Ravelli A. Review Introducing new tools for assessment of parent- and child-reported outcomes in paediatric rheumatology practice : a work in progress. *Clin Exp Rheumatol* 2013; **31**: 964–968.
- 44 Dervisoglou T, Matiakis A. Oral Ulceration Due to Methotrexate Treatment : A Report of 3 Cases and Literature Review. 2015.
- 45 Lim AYN, Gaffney K, Scott DGI. Methotrexate-induced pancytopenia : serious and under-reported ? Our experience of 25 cases in 5 years. 2005; : 1051–1055.
- 46 Chan ESL, Cronstein BN. Mechanisms of Action of Methotrexate. 2013; **71**: 5–8.
- 47 Jakubovic BD, Donovan A, Webster PM, Shear NH. Methotrexate-induced pulmonary toxicity. *Can Respir J* 2013; **20**: 153–155.
- 48 Buhroo AM, Ortho MS. Adverse Effects of Low-Dose Methotrexate in Patients with Rheumatoid Arthritis. 2012.
- 49 Sitaresmi MN, Mostert S, Gundy CM, Veerman AJP. Health-related quality of life assessment in Indonesian childhood acute lymphoblastic leukemia. *Health Qual Life Outcomes* 2008; **8**: 1–8.
- 50 Luca NJ, Feldman BM. Defining clinically inactive disease in juvenile dermatomyositis. *Nat Rev Rheumatol* 2012; **8**: 638–639.
- 51 Chickermane PR, Mankad D, Khubchandani RP. Disease Patterns of

- Juvenile Dermatomyositis From Western India. *Indian Pediatr* 2013; **50**: 961–3.
- 52 Owino L, Esser M, Wilmschurst J, Scott C. Characteristics and outcome of children with juvenile dermatomyositis in Cape Town : a cross-sectional study. *Pediatr Rheumatol* 2016; : 1–8.
- 53 Sjarif DR, Gultom LC, Hendarto A, Lestari ED, Sidiartha IGL, Mexitalia M. *Diagnosis, Tata Laksana dan Pencegahan Obesitas pada Anak dan Remaja*. pertama. IDAI: Jakarta, 2014.
- 54 Marsubrin PMT. *Kualitas hidup anak sindrom nefrotik menggunakan penilaian pediatric quality of life inventory (PedsQL)*. 2014.
- 55 Fraser L-A, Adachi JD. Glucocorticoid-induced osteoporosis: treatment update and review. *Ther Adv Musculoskelet Dis* 2009; **1**: 71–85.
- 56 Briot K, Roux C. Glucocorticoid-induced osteoporosis. *RMD Open* 2015; **1**. doi:10.1136/rmdopen-2014-000014.